Bausch + Lomb presented or sponsored several scientific posters and oral presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which took place from May 4 to May 8 in Orlando, Florida. Results from two clinical studies (CONSTELLATION and KRONUS) were presented, as well as preclinical mechanism of action data. The abstracts are available on the ARVO 2014 Online Planner.

Results from a cross-over Phase 2 study named CONSTELLATION were presented by Dr. John H. Liu in an oral presentation entitled “Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Lowering IOP over 24 hours in Subjects With Open Angle Glaucoma or Ocular Hypertension (CONSTELLATION)” (abstract number 3549). The objective of this study was to compare the effect of latanoprostene bunod 0.024% QD with timolol maleate 0.5% BID in reducing 24-hour intraocular pressure (IOP) in subjects with open angle glaucoma or ocular hypertension.

Phase 1 results from a Japanese clinical trial named KRONUS were presented in a poster entitled “Efficacy of Latanoprostene Bunod Ophthalmic Solution, 0.024%, in Lowering Intraocular Pressure Over 24-Hours in Normal Japanese Subjects (KRONUS)” (Araie et al., abstract number 548 – A0184). The purpose of this study was to evaluate the effect of latanoprostene bunod 0.024% QD on diurnal IOP over a 24-hour period in healthy Japanese subjects following 14 days of treatment.

Preclinical results were presented in a poster entitled “NO-induced Regulation of Primary Human Trabecular Meshwork Cell Contractility by Latanoprostene Bunod” (Cavet et al., abstract number 546 – A0182). This poster presented the effect of latanoprostene bunod on primary human trabecular meshwork cell (HTMC) contractility and underlying signaling pathways, to assess whether latanoprostene bunod may mediate additional IOP lowering via the conventional outflow pathway.

In addition, Jason L. Vittitow, Director of Clinical Affairs at Bausch + Lomb, made an oral presentation entitled “Development of a nitric oxide-donating prostaglandin for the treatment of glaucoma” at the ‘New insights into the role of nitric oxide signaling in glaucoma’ Special Interest Group (SIG).